BRVE

Braveheart Bio, Inc.

Nasdaq· CIK 0002131524

$21.76 −0.11 (−0.48%)

Oct 27 4:00 PM ET · prev $21.87

Market cap

$1.9B

Small cap

Consensus

Buy

91% Buy or better · 11 analysts

Median target

🔒 Subscribers only

Since first trade

−27.0%

from $29.80 · Aug 6

30 days

+3.3%

from $21.07

Range since listing

$18.58–30.00

−27% from high · low Oct 7

Avg volume 20D

366.8K

Sep 30 spike 967.5K

Short interest

🔒 Subscribers only

Insider net

+$159.0M

10 buyers · 0 sellers · 12 mo

Filing reports

analyzed by SecBot

SecBot read BULLISH 8 reports · 90 days

Balance 0 bearish · 6 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 8/8

Strongest BULLISH A massive insider buying cluster at Braveheart Bio, Inc. (BRVE) saw 10 insiders — including the CEO, CFO…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Aug 7 10 insiders buy $159.0M at $18.00
E Aug 7 Offering: Braveheart Bio Announces Closing of Upsized Initial Public…
R Aug 7 Seven insiders at Braveheart Bio, including the CEO, CFO, CDO, and a…
R Aug 11 A massive insider buying cluster at Braveheart Bio, Inc. (BRVE) saw…
R Aug 11 A massive insider buying cluster at Braveheart Bio (BRVE) saw 8 insi…
X Aug 31 Short interest jumps 64.8% to 1.40M
X Sep 15 Short interest jumps 76.2% to 2.46M
X Sep 30 Short interest jumps 67.8% to 4.13M

Signal stack

Where each data set points today.

InsidersBULLISH

10 insiders bought $159.0M. No open-market sales.
AnalystsBULLISH

10 of 11 rate it Buy or better.
TrendDOWNTREND

9% below its 50-day average.

The Street

11 analysts

Buy 91% rate it Buy or better

Strong Buy4Buy6Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Oct 20, 2026	Cantor Fitzgerald REITERATE	REITERATE	Overweight

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

Oct 15, 2026

Short interest

🔒 Fresh data, subscribers only

Sep 30, 2026

Short interest

Short Interest: BRVE up 68% to 4.1M shares

Settlement 2026-09-30 | Days to cover: 5.10 | ≈4.59% of shares outstanding (est.)

Sep 16, 2026

Press release

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing…

Sep 15, 2026

Short interest

Short Interest: BRVE up 76% to 2.5M shares

Settlement 2026-09-15 | Days to cover: 7.49 | ≈2.73% of shares outstanding (est.)

Sep 8, 2026

Earnings

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated

Insider ledger

Form 4

$159.0M

bought · 10 insiders

sold · 0 insiders

Date	Insider	Type	Value
Aug 7, 2026	Lubner David Charles Director	BUY	$1000.0K
Aug 7, 2026	Rickey James Paul Chief Financial Officer	BUY	$500.0K
Aug 7, 2026	Malek David I Director	BUY	$75.0K
Aug 7, 2026	Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10%+ Owner	CONVERT	7,420,091 sh
Aug 7, 2026	Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10%+ Owner	CONVERT	32,500,000 sh
Aug 7, 2026	Viehbacher Christopher Director	BUY	$1.5M
Aug 7, 2026	Anderson Michele A. Chief Development Officer	BUY	$20.0K
Aug 7, 2026	Murdoch Travis CEO and President	BUY	$1.5M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data, subscribers only
Next Q	🔒 Fresh data, subscribers only
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only